December 19, 2025 03:09 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
‘Worst is over,’ says IndiGo CEO after flight chaos; staff told to ignore speculation | Chaos at Hyderabad's Lulu Mall! Nidhhi Agerwal swarmed by fans, police register case | TCS bets big on AI, shares spike as company reveals ambitious plan | Delhi goes into emergency mode! Work from home, vehicle bans as AQI hits ‘severe’ | Massive fire guts shanties near Eco Park in Kolkata; no casualties | Indian Visa Application Centre in Dhaka shuts down early amid rising security concerns | Market update: Sensex tumbles 120 points, Nifty below 25,850 at closing bell | ‘Won’t apologise’: Prithviraj Chavan stands firm on controversial Operation Sindoor remark despite backlash | India summons Bangladesh High Commissioner after provocative 'seven sisters' remark | Amazon eyes $10 billion investment in OpenAI — a gamechanger for AI industry!
CMRI
Sombrata Ray (L), Unit Head at CMRI Kolkata and Dr. Deep Das (R) addressing a press conference. Photo: Supriyo Hazra/IBNS

Kolkata's CMRI participates in multicentric trial of Supernova stent retriever, aims to reduce stroke therapy cost

| @indiablooms | Sep 05, 2025, at 01:47 am

CK Birla Hospital – CMRI, recently participated in India's first multicentric trial of Supernova stent retriever, a measure that is expected to reduce the cost of stroke therapy by more than 50 percent.

CK Birla Hospitals – CMRI was the only hospital in Eastern India that participated in the trial.

"We are confident from the success of the trial that we can probably reduce the cost of the therapy by 50 percent," Dr Deep Das, Professor of Neurology and Consultant Neurointerventionalist at CMRI, Kolkata, said during a press conference on Thursday.

“This pioneering trial marks a significant milestone as the first-ever multicenter study in India focused on validating a new stent retriever device, showcasing India’s growing capabilities in high-quality medical research and device validation,” he said.

Also ReadWe welcome government’s progressive GST reforms: CMRI Kolkata

He said the trial initially focused on treating patients aged between 18 to 80 years.

"Now, once the trial has been successfully conducted, we can say that there is no age limit for people who can undertake the therapy," he said.

The stent retriever is designed to drastically reduce the cost of stroke intervention devices by more than 50%.

Developed with precision and advanced technology, the device ensures targeted treatment for Indian patients with large artery occlusions, maximising success rates while maintaining safety standards.

Dr Dileep Yavagal, Global Principal Investigator of the trial believes that as we make advanced stroke care affordable, life-saving procedures will become more accessible for patients across India, regardless of their socio-economic status.

Speaking on CMRI’s successful participation in the trial, Sombrata Ray, Unit Head at CMRI Kolkata, told, “CMRI is focused on advancing our neurological capabilities, and this trial was a testament to our commitment. CMRI is the only hospital from Eastern India to participate in the trial."

"Participating in this trial also reinforces our ongoing efforts to combine clinical expertise, research, and innovation to improve outcomes for patients from across the country and beyond," he said.

Dr. Shashvat M. Desai, who designed the device, said: "Through this trial, we have demonstrated that India is ready to lead in the development and validation of advanced medical technologies."

Developed by Gravity Medical Technology, he said the device will address the urgent need for advanced stroke care in India, where 17 lakh people are affected each year.

He said by expanding access to timely thrombectomy, the device has the potential to save countless lives and prevent lifelong paralysis.

Speaking during the press conference via video conference, Dr. Biman Kanti Ray, Senior Consultant Neurologist, Bangur Institute of Neurosciences, Kolkata, said: “This innovation represents a new era of hope for stroke patients and their families."

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.